0001127602-19-011543.txt : 20190315 0001127602-19-011543.hdr.sgml : 20190315 20190315160105 ACCESSION NUMBER: 0001127602-19-011543 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190311 FILED AS OF DATE: 20190315 DATE AS OF CHANGE: 20190315 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ribeill Yves J CENTRAL INDEX KEY: 0001604049 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38161 FILM NUMBER: 19684988 MAIL ADDRESS: STREET 1: C/O SCYNEXIS, INC. STREET 2: 3501 C TRICENTER BOULEVARD CITY: DURHAM STATE: NC ZIP: 27713 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Calyxt, Inc. CENTRAL INDEX KEY: 0001705843 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 271967997 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2800 MOUNT RIDGE ROAD CITY: ROSEVILLE STATE: MN ZIP: 55113 BUSINESS PHONE: (651) 683-2807 MAIL ADDRESS: STREET 1: 2800 MOUNT RIDGE ROAD CITY: ROSEVILLE STATE: MN ZIP: 55113 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2019-03-11 0001705843 Calyxt, Inc. CLXT 0001604049 Ribeill Yves J 2800 MOUNT RIDGE ROAD ROSEVILLE MN 55113 1 Restricted Stock Units 2019-03-11 4 S 0 5000 17.3915 D 55000 D Restricted Stock Units 2019-03-12 4 S 0 5000 16.7638 D 50000 D Restricted Stock Units 2019-03-13 4 S 0 5000 16.082 D 45000 D Restricted Stock Units 2019-03-14 4 S 0 4980 16.3288 D 40020 D Stock Option (Right to Buy) 17.10 2028-08-21 Common Stock 180000 180000 D The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vested 33.3% on October 10, 2018, with 33.3% vesting on October 10, 2019, and 33.4% vesting on October 10, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.665 to $17.79, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.19 to $16.99, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.76 to $16.365, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.82 to $16.85, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. The award of stock options with respect to Calyxt, Inc. common stock, which was previously reported on a Form 4, was granted on August 21, 2018. The vesting schedule with respect to such stock options was subsequently accelerated such that 33.3% of the stock options vested on October 10, 2018, with 33.3% vesting on October 10, 2019 and 33.4% vesting on October 10, 2020. /s/ Dr. Andre Choulika, as Attorney-in-Fact for Dr. Yves J. Ribeill 2019-03-15 EX-24 2 doc1.htm POWER OF ATTORNEY Yves J. Ribeill POA

EXHIBIT 24

Calyxt, Inc.

Power of Attorney
for Executing Forms 3, 4 and 5

Know all men by these presents, that the undersigned, director or officer, or both, of Calyxt, Inc., hereby constitutes and appoints each of Dr. Andre Choulika, Ph.D., the Chairman of the Company?s Board of Directors, Eric Dutang, the Company?s Interim Chief Financial Officer, and Kavita Battula, the Company?s Licensing and Contracts Manager, signing singly, the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Calyxt, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities of Calyxt, Inc. unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of this 10th day of October, 2018
/s/ Yves J. Ribeill
Yves J. Ribeill